Novartis building

Novartis to Supply Leqvio to the UK’s National Health Service

September 2, 2021

Novartis has reached an agreement with the UK’s National Health Service to offer its potential blockbuster cholesterol-lowering drug Leqvio (inclisiran) for an undisclosed price.

The deal, which followed a cost-benefit review by the UK’s National Institute for Health and Care Excellence, will enable approximately 300,000 patients at high risk of a second cardiovascular event to be treated over three years.

Leqvio (inclisiran) is given as a 6-month maintenance dose for individuals with elevated low-density lipoprotein cholesterol who do not show an adequate response to statins.

View today's stories